Skip to content

Scancell: Phase 2 clinical trial of lead immunotherapy product commences

First patient dosed in SCIB1 Phase 2 clinical trial Trial to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate and overall survival in patients with advanced melanoma Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious … Continued

Spectral MD announce early results from clinical study

Accuracies of 92% and 88% in detection of severe thermal burn injury in adults and children, respectively Article published in Journal of Burn Care and Research on histological burn depth research LONDON, U.K. AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for … Continued

Blu Wireless showcase new 360° Tactical Vehicle Node

Blu Wireless have been showcasing their new 360° Tactical Vehicle Node, which enables scalable tactical connectivity between vehicles. In contrast to commercial networks, tactical 5G military networks necessitate systems which are standalone, secure, can be easily interfaced to existing tactical equipment and are resistant to single point of failure. Blu Wireless is a firm that … Continued

What is a Fund Looking for?

Interview with Richard Moore – Co Head of Investments – Calculus Capital Calculus Capital has over 20 years’ experience investing in UK growth companies. Calculus works in partnership with investee companies, usually taking a seat on the board and providing advice on a strategic level – with the aim of realising the full potential of … Continued

Calculus Capital delivers 4x return with sale of software company CloudTrade

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus portfolio company, CloudTrade, has been acquired by Advanced, a leading provider of business software, delivering a 4x return to Calculus investors in just over 3 … Continued

Wonderhood’s latest campaign for Starling Bank ‘Set Yourself Free’

Created by Calculus portfolio company Wonderhood Studios, the advert, “Set yourself free”, launches Starling’s new brand platform “Here to change”. It debuts on Channel 4 and Sky channels, with airings during shows including Gogglebox. Wonderhood’s first campaign for Starling Bank, aimed at new businesses, aired in February 2020.

Northern Trust invests in Essentia Analytics

Essentia’s software uses data analytics and behavioural finance research to help allocators and active asset managers make better decisions and improve their returns. Essentia expects to expand headcount and accelerate research and development following an investment by Northern Trust. Northern Trust (Nasdaq: NTRS) has reached an agreement to take an equity stake in Essentia Analytics, Ltd., … Continued

Oxford BioTherapeutics and Boehringer Ingelheim Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued

Arecor announces positive results from Phase 1 Trial of insulin product for diabetes patients

Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin … Continued

Calculus strengthens Investor Relations team

Calculus is delighted to announce the appointments of Matthew Moynes and Frank Spurway as Investor Relations Assistant Director and Analyst respectively. Matthew joins Calculus from Barclays Wealth where he was the Head of Venture Capital Products responsible for managing the tax efficient third-party manager panel and driving distribution through product specialist support to Wealth Managers … Continued

Calculus Invests in Brouhaha Entertainment

Brouhaha Entertainment was founded by experienced producers: Oscar nominated Gabrielle Tana, Independent film industry pioneer Troy Lum and producer Andrew Mason Founders have successfully produced 27 films and 9 television projects to date, featuring top talent from around the globe Investment will be used to expand the team and fund development in film and particularly … Continued

Calculus exits Mologic – generating up to a 3.6x return for investors

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus successfully exit Mologic by sale to new philanthropic entity Global Access Health London 19 July 2021: Calculus Capital (“Calculus”), pioneers of the tax efficient investment … Continued

Calculus VCT Annual General Meeting 2021

The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 12.30pm on 8 July 2021. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued

Calculus invests in Spectral MD

Calculus VCT has invested £0.5m into Spectral MD through an oversubscribed inital public offering onto AIM, on Tuesday 22 June. The Dallas-based firm, which is building notable presence in the UK as part of its product launch effort, produces predictive analytics, proprietary AI algorithms and imaging systems to assist with medical treatment. Spectral MD’s technology, … Continued

Calculus invests in Arecor following successful IPO

Arecor announced its admission to trading on AIM, a market operated by London Stock Exchange, on 3 June 2021. Admission follows a successful oversubscribed placing by Panmure Gordon, raising gross proceeds of £20 million at a price of 226 pence per share. On Admission the Company will have a market capitalisation of approximately £62.5 million. … Continued

Calculus Exits Sports Tour Operator inspiresport

inspiresport is the industry leading sports development tour operator, offering unrivaled access to world class clubs, coaches, and facilities to take young players of all abilities on extraordinary sporting journeys. The company has been acquired by Portman Travel Group, which is expanding into the sports travel market, providing an exit event for Calculus investors. Calculus, … Continued

Arecor granted key US patent

Cambridge, UK., 13 May 2021 – Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology … Continued

Calculus invests in Invizius

The University of Edinburgh spin-out is developing potentially lifesaving products that help reduce complications and high death rates amongst dialysis patients. Incoming institutional investor Calculus Capital has participated in a funding round with existing investors Downing Ventures and Mercia, alongside Solvay Ventures, Scottish Enterprise and Old College Capital Glasgow, Scotland, May 6th, 2021 – Invizius … Continued

Blu Wireless accelerates growth with opening of new US business entity

Business expansion and appointment of local team will enable Blu Wireless to accelerate growth in the defence, public safety, and transport sectors, providing enhanced customer service in North America. Blu Wireless, the leader in 5G mmWave networking equipment, has today announced the expansion into the United States with the launch of Blu Wireless Technology Inc. … Continued

C4X signs exclusive worldwide licensing agreement with Sanofi worth up to €414 million

The licensing agreement, which C4X will receive an upfront payment of €7 million from, is for their oral pre-clinical IL-17A inhibitor programme. 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with … Continued

Arecor receives £2.8 million grant award from Innovate UK

Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin Cambridge, UK., 31st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the … Continued

Calculus Capital delivers 6x return with ActiveOps listing

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus Capital portfolio company ActiveOps has completed a successful Initial Public Offering on the Alternative Investment Market, generating an impressive 6x return for Calculus EIS investors. … Continued

Calculus Capital invests in Axol Bioscience following merger with Censo Biotechnologies

Biotech sector-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across existing shareholders and new investors, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of stem cells produced from reprogrammed human blood and tissue cells, … Continued